Investor Takeaway For investors seeking exposure to the GLP-1 boom in India, the key is to identify companies with proven capabilities in: Peptide synthesis Sterile injectable manufacturing Global regulatory compliance CDMO services with US/EU clients Recommended Monitoring: R&D updates and capacity expansions Any tie-ups with global GLP-1 players Clinical trial progress for biosimilar versions Regulatory approvals (USFDA, EMA) Export data to key markets (USA, Canada, China) Conclusion The weight loss drug boom is changing global healthcare and creating a huge business opportunity for Indian pharma companies
Real Results : A traveler with GLP-1s, syringes, and a USB cooler approaches TSA security at Denver International Airport
Neuroplasticity and major depression, the role of modern antidepressant drugs
COSRX is known for its short ingredients list that features high quality and effective extracts and compounds that help trouble-prone, dry and dehydrated skin, as well as aging and sensitive skin
The BMS guidance did not say by how much the dose of oral progestogen should be increased a document published by the Primary Care Womens Health Society (PCWHS) suggested that a pragmatic approach would be to use the same increases as we would use for women taking a higher than usual dose of oestrogen, but also pointed out that the lack of data to guide this and emphasised that the levonorgestrel intrauterine device gives the best endometrial protection and should be recommended in this situation
Handling: Strict laboratory conditions required